Human Papillomavirus Vaccination in India: From Policy Evolution to National Implementation

Abstract Cervical cancer remains a major public health challenge in India, accounting for a disproportionate share of global morbidity and mortality despite being largely preventable. This review examines India’s complex and delayed journey toward the nationwide introduction of human papillomavirus (HPV) vaccination in 2026, highlighting the interplay of ethical controversies, regulatory evolution, and sociocultural dynamics. The suspension of the 2009 demonstration trials following serious ethical concerns generated long-lasting mistrust, particularly among vulnerable and tribal populations, and significantly impeded policy momentum. Subsequent legal scrutiny and policy reforms, including strengthened clinical trial regulations and enhanced safeguards for informed consent, laid the groundwork for renewed public health action. The recent rollout leverages an indigenous vaccine, single-dose strategy, and digital platforms to improve accessibility, affordability, and program efficiency. However, persistent vaccine hesitancy, fueled by misinformation and historical distrust, continues to challenge uptake. Drawing on lessons from past failures and recent successes, this analysis emphasizes the critical importance of ethical rigor, transparent governance, and community engagement in large-scale immunization programs. India’s experience offers valuable insights for other low- and middle-income countries striving to implement equitable and effective HPV vaccination strategies in complex social contexts.